Selegiline, also known as Deprenyl, is an MAO inhibitor originally approved as a prescription drug for Parkinson's disease

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.